# Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

> **NCT01196988** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3027 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza vaccine GSK2321138A
- **BIOLOGICAL:** FluarixTM
- **BIOLOGICAL:** Influenza vaccine GSK2604409A

## Key facts

- **NCT ID:** NCT01196988
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-04
- **Primary completion:** 2011-06-15
- **Final completion:** 2011-06-15
- **Target enrollment:** 3027 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01196988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01196988, "Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01196988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*